Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Docefrez

(Docetaxel every 3 week in combination with capecitabine)

Small molecule

0

Indications

1

Total Trials

0

Active Trials

0

Competitors

11

FDA Applications

NDA/BLA/ANDA regulatory filings

Clinical

Trials by Indication[1]

Metastatic1 trial

Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC

Completed·NNorwegian Breast Cancer Group·Phase 2/3·NCT00201435·224 enrolled

Regulatory

FDA Approval Timeline[3]

Aug 3, 2010

TAXOTERE

NDA NDA020449

Mar 8, 2011

DOCETAXEL

NDA NDA022234

May 3, 2011

DOCEFREZ

NDA NDA022534

Jun 8, 2011

DOCETAXEL

NDA NDA201195

Jun 29, 2011

DOCETAXEL

NDA NDA201525

Jan 11, 2012

DOCETAXEL

NDA NDA022312

Apr 12, 2013

DOCETAXEL

NDA NDA203551

Mar 13, 2014

DOCETAXEL

NDA NDA202356

Dec 22, 2015

DOCETAXEL

NDA NDA205934

Nov 22, 2022

DOCIVYX

NDA NDA215813

Dec 10, 2025

BEIZRAY

NDA NDA218711

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Docetaxel every 3 week in combination with capecitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Docetaxel every 3 week in combination with capecitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA218711). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Avyxa company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AAvyxa

Related News